Fresenius Medical Care AG & Co. KGaA $FMS Stock: Pzena Investment Management LLC Increases Holdings

Key Points

• Pzena Investment Management increased its Fresenius Medical Care stake by 10.8%, adding about 1.63 million shares to reach 16.62 million shares, or roughly 3.09% of the company.
• The company reported quarterly EPS of $0.66, beating the $0.62 consensus, and revenue of $5.55 billion versus estimates of $5.48 billion.
• Analyst sentiment remains cautious: MarketBeat reports a consensus “Reduce” rating and an average price target of $23.42, with seven analysts rating the shares Hold and four Sell.

Pzena Investment Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 10.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,617,575 shares of the company's stock after purchasing an additional 1,625,494 shares during the period. Fresenius Medical Care AG & Co. KGaA makes up about 1.1% of Pzena Investment Management LLC's investment portfolio, making the stock its 28th biggest holding. Pzena Investment Management LLC owned approximately 3.09% of Fresenius Medical Care AG & Co. KGaA worth $371,901,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Trek Financial LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 9.2% in the third quarter. Trek Financial LLC now owns 12,350 shares of the company's stock worth $276,000 after buying an additional 1,040 shares during the period. Transmarket Holdings LP lifted its position in Fresenius Medical Care AG & Co. KGaA by 33.4% during the 3rd quarter. Transmarket Holdings LP now owns 17,311 shares of the company's stock worth $387,000 after acquiring an additional 4,332 shares in the last quarter. DMC Group LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 5.9% during the 3rd quarter. DMC Group LLC now owns 22,859 shares of the company's stock worth $512,000 after acquiring an additional 1,271 shares in the last quarter. Signaturefd LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 16.0% in the 3rd quarter. Signaturefd LLC now owns 11,540 shares of the company's stock worth $258,000 after acquiring an additional 1,593 shares during the period. Finally, Crossmark Global Holdings Inc. grew its position in Fresenius Medical Care AG & Co. KGaA by 10.1% in the third quarter. Crossmark Global Holdings Inc. now owns 63,752 shares of the company's stock valued at $1,427,000 after acquiring an additional 5,859 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Up 6.6%

Shares of NYSE:FMS opened at $23.18 on Thursday. The stock has a market capitalization of $12.33 billion, a price-to-earnings ratio of 13.40, a price-to-earnings-growth ratio of 5.07 and a beta of 0.78. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.02 and a 1-year high of $26.42. The company's fifty day moving average is $22.33 and its two-hundred day moving average is $22.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.23% and a return on equity of 9.03%. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. Equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Citigroup reaffirmed a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price objective on the stock. in a report on Tuesday, July 28th. Sanford C. Bernstein boosted their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong sell" rating in a research report on Thursday, October 15th. Finally, Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Seven research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of "Reduce" and an average target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.